Skip to content
Clinical Trials – home

Find therapies in clinical trials near you

recruiting
3 987
countries
28
conditions
2 109

6 trials match your criteria

Study of TIL therapy combined with peginterferon alfa-2a and nivolumab for patients with metastatic melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:TIL cells

Study on CD8 PET Imaging for Patients with Metastatic Solid Tumors Using 89Zr-Df-crefmirlimab, Nivolumab, and Cetrelimab

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab

PET/CT Imaging Study for Patients with Giant Cell Arteritis or Rheumatoid Arthritis Using Zirconium (89Zr) Crefmirlimab Berdoxam

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zirconium (89ZR) crefmirlimab berdoxam

Study on Early Detection of Side Effects in Metastatic Melanoma Patients Using Zirconium (89Zr) Crefmirlimab Berdoxam Imaging

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zirconium (89ZR) crefmirlimab berdoxam

Kidney transplant rejection

Not yet recruiting

Evaluation of zirconium-89 crefmirlimab berdoxam PET imaging for monitoring renal allograft rejection in kidney transplant recipients

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zirconium (89ZR) crefmirlimab berdoxam

Oesophageal carcinoma+3

Not recruiting

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nelarabine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.